Skip to main content
Caplight Logo









Anagenex

Anagenex

Private
San Francisco, CaliforniaHealthcare & Life Scienceshttps://anagenex.com/

Last Round

Series A

Jun 8, 2022

Total Funding Raised

$44.4M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Anagenex is a biotechnology company that provides a drug discovery platform combining ultra-high-throughput biochemistry, DNA-encoded library technology, and machine learning to identify and optimize small molecule therapeutics for challenging medical targets.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology, Medical AI

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share

AI Layer

Infrastructure

Keywords

small molecule drug discoverydirected evolutiondrug discovery platformundruggable targetsDNA-encoded librariesaffinity-selected mass spectrometryAI drug discoverybiotech R&Din silico drug discoverylead optimizationpharma partnershipAI-native biotechcomputational biologyASMS

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Anagenex Comparables

Compare Anagenex with similar companies based on industry and business-model similarity.

Anagenex comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Terray Therapeutics
81%
Leash Bio
81%
Orogen Therapeutics
80%

Anagenex Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AJun 8, 2022

Anagenex Investors

Notable investors and investment history

Anagenex investors
InvestorRounds
Khosla VenturesSeed, Series A
Air Street CapitalSeed, Series A
Lux CapitalSeries A, Seed
Catalio Capital ManagementSeries A
Obvious VenturesSeed, Series A
Menlo VenturesSeed, Series A
Alloy FundSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 21, 2026

    Monthly visitors grew 146% MoM, reaching 39.6K.

Anagenex Filings

Explore SEC and related filing metadata, where available.

Anagenex filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Anagenex's valuation, stock price, and market status.

Is Anagenex a public or private company?

Anagenex is a private company.

What is the current stock price of Anagenex?

Anagenex is a private company with no public stock price. No recent secondary market data is available.

How much is Anagenex worth (valuation)?

Valuation information for Anagenex is not publicly available.

Can I buy Anagenex stock?

Anagenex shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Anagenex's last funding round?

Anagenex's most recent funding round was Series A on June 8, 2022.

Who are the main investors in Anagenex?

Key investors in Anagenex include Lux Capital, Catalio Capital Management.

Will Anagenex IPO soon?

No public IPO plans have been announced for Anagenex.

How can I track Anagenex secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Anagenex's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSan Francisco, California
Employee Range5
Year Founded2019
Last FundingJun 8, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?